GLP1R and obstructive sleep apnea syndrome: Evidence from two double-blinded randomized controlled trial (RCT) studies also showed that glucagon-like peptide-1 receptor agonist use is associated with improvement in apnea–hypopnea index (AHI), independent of GLP-1RA weight-loss effects and associated decrease in body mass index (BMI) [45,46]; this suggests a direct yet-to-be determined mechanism on various pathways involved in OSA pathogenesis.